Despite ongoing technological advances, the current drug discovery paradigm is time and money consuming. The pain of drug screen stems from the lack of translatable biological models that can generate early safety and efficacy insights to accurately predict the potential clinical performance of a drug candidate.
VivoZ BioLabs aims to establish an ex vivo platform for predicting in vivo outcomes of animal models. This platform is based on our microFluidic Tissue Array (μFTA) technology. Our collaboration with biotech/pharmaceutical companies and contract research organizations (CROs) can lead to on-chip assays designed specifically for their project needs.